Optical Coherence Tomography for the Assessment of Coronary Plaque Vulnerability by Hasegawa, Takao & Shimada, Kenei
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Optical Coherence Tomography for the Assessment of
Coronary Plaque Vulnerability
Takao Hasegawa and Kenei Shimada
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/61615
Abstract
Optical coherence tomography (OCT) is a high-resolution imaging technology, which can
provide detailed observation of the vulnerable coronary atherosclerotic plaques in clinical
settings. The current understanding of the major cause of acute coronary syndrome is
that it results from plaque rupture of a vulnerable plaque. OCT can provide detailed ob‐
servation of the vulnerable coronary plaque. The main findings of vulnerable plaque by
OCT are considered to be a lipid-rich plaque, a thin-cap fibroatheroma, microchannel
structure, spotty calcification, macrophage infiltration, and cholesterol crystal. These fea‐
tures observed by OCT can provide cardiologists to consider pathological mechanisms of
coronary atherosclerosis and suitable medical and interventional treatments for vulnera‐
ble patients. In this review, we will discuss the characteristics of OCT assessment for cor‐
onary atherosclerosis and the clinical impacts of OCT imaging for the treatment of
coronary artery disease.
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1. Introduction
Optical coherence tomography (OCT) is an optical analog of intravascular ultrasound (IVUS)
that allows physicians to visualize various morphological features of coronary atherosclerotic
plaques in vivo. Recently, several vulnerable features of coronary atherosclerosis have been
suggested in both histopathological and clinical studies with the emerging use of OCT. The
main findings of vulnerable plaque by OCT are considered to be a lipid-rich plaque, a thin-
cap fibroatheroma (TCFA), microchannel structure, spotty calcification, macrophage infiltra‐
tion, and cholesterol crystal. We describe the features of vulnerable plaques by OCT and the
impact of OCT findings for diagnosis and clinical treatment.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
OCT is a high-resolution intracoronary imaging technology with near-infrared light to produce
cross-sectional images of coronary artery disease. The spatial resolution of OCT, nearly 10 µm
on the lateral axis, is almost 10 times greater than that of IVUS. OCT could provide detailed
plaque morphology near to pathological assessment. More than 70% of acute coronary
syndrome (ACS) was caused by plaque rupture, and nonruptured type (plaque erosion or
calcified nodules) was shown in 30% of ACS. OCT is able to visualize vulnerable plaque which
was prone to plaque rupture possibly agree with autopsy findings. Vulnerable feature by OCT
were a lipid-rich plaque, a TCFA, vasa vasorum, spotty calcification, macrophage infiltration,
cholesterol crystal. We describe the natural history of vulnerable plaques and the clinical
impact of each vulnerable feature detected by OCT images.
Recent studies have shown that vulnerable plaques could develop not only in native coronary
arteries but also in the neointima after coronary stent implantation. OCT studies have reported
the development of neoatherosclerosis changes within both bare-metal stents and drug-eluting
stents after stent implantation. Neoatherosclerosis includes lipid accumulation, calcium
deposition, macrophage infiltration, and development of neovascularization within neointima
area of the stent. These changes after stent implantation could play an important role in the
development of late stent failure (late stent restenosis and late stent thrombosis).
Primary percutaneous coronary intervention (PCI) is widely performed for patients with
coronary artery disease. Sometimes, no-reflow phenomenon occurred during PCI, and no-
reflow is associated with poor functional and clinical patient outcomes when compared with
patients with adequate reflow. Recent studies have shown that some vulnerable findings
(lipid-rich plaque, TCFA, and spotty calcification) are predictors of no-reflow phenomenon.
We describe how to treat vulnerable plaques during PCI with OCT.
Optimal medical therapy (OMT) is regarded as one of the effective treatments for the stabili‐
zation of coronary artery plaques, and it reduces the risk for coronary events and mortality.
However, cardiovascular events occur in some patients even with OMT; the residual risk has
become a problem. OCT detects and follows vulnerable plaque serially. Dyslipidemia is a
strong risk for coronary artery disease and promotes coronary atherosclerosis. We describe
the impact of oral lipid-lowering agents on stabilizing vulnerable plaques with OCT.
2. Optical coherence tomography technology
OCT is  a  new high-resolution intracoronary imaging technology based on near-infrared
interferometry. As near-infrared light is unable to penetrate red blood cells (RBCs), OCT
imaging is needed to remove RBCs in the coronary artery with a bolus injection of contrast
medium. The high pull-back speed of OCT enables cardiologists to assess the long coronary
plaque  components  in  a  few  seconds.  At  present,  2  types  of  OCT  systems,  Frequency
Domain OCT (St. Jude Medical, ST. Paul, Minnesota, USA) and Frequency Domain Optical
Imaging (Terumo, Tokyo, Japan) are available for clinical use. The spatial resolution of OCT,
nearly 10 µm on the lateral axis, is almost 10 times greater than that of IVUS. As shown
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in Figure 1, OCT visualizes 3-layer structures of coronary artery. OCT-imaging technolo‐
gy allows cardiologists to examine tissue characterization of coronary atherosclerotic lesions
in vivo.
Figure 1. Representative optical coherence tomography images of the three layers of the vascular wall. Optical coher‐
ence tomography could identify the three layers of the vascular wall.
3. Coronary plaque vulnerability by OCT
Recently, several vulnerable features of coronary atherosclerosis have been suggested in both
histopathological and clinical studies with the emerging use of OCT [1-3]. The ability of OCT
in tissue characterization of coronary atherosclerotic lesions has been well-validated in
clinicopathological studies [4-6]. OCT could provide detailed plaque morphology near to
pathological assessment. OCT can provide three morphological features of coronary athero‐
sclerosis: fibrous plaques, calcified plaques, and lipid-rich plaques (Figure 2). Fibrous plaque
is defined as homogeneous, signal-rich regions with low attenuation. Calcified plaque is
defined as well-delineated, signal-poor regions with sharp borders. Lipid-rich plaque is
defined as signal-poor regions with diffuse borders.
The current understanding of the major cause of ACS is that it results from rupture of a
vulnerable plaque. OCT is a high-resolution imaging technology that can provide detailed
observation of the vulnerable coronary plaque. The main findings of vulnerable plaque by
OCT are considered to be a TCFA, ruptured plaque, intracoronary thrombus, vasa vasorum,
spotty calcification, macrophage infiltration, and cholesterol crystal (Figure 3).
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Figure 3. Vulnerable findings of optical coherence tomography images in coronary plaques. (A) Thin-cap fibroathero‐
ma (TCFA), (B) Ruptured plaque, (C) Intracoronary thrombus, (D) Vasa vasorum, (E) Spotty calcification, (F) Macro‐
phage infiltration, (G) Cholesterol crystal.
3.1. Thin-cap fibroatheroma
TCFA is considered when the fibrous cap thickness is ≤65 µm in the lipid-rich plaque. OCT–
TCFA  has  relationship  with  several  characteristics  of  vulnerable  plaque  in  the  other
intracoronary imagings, such as attenuated plaque by gray-scale IVUS, necrotic plaque by
virtual histology IVUS, and yellow plaque by intracoronary angioscopy [7-9]. Fibrous cap
thickness is associated with serum C-reactive protein, oxidized low-density lipoprotein, and
insulin  resistance  [10-12].  OCT–TCFA  is  a  predictor  of  ACS  and  consequent  plaque
progression [13, 14].
Figure 2. Plaque morphology by optical coherence tomography. (A) Fibrous plaque is defined as homogeneous, signal-
rich regions with low attenuation. (B) Calcified plaque is defined as well-delineated, signal-poor regions with sharp
borders. (C) Lipid-rich plaque is defined as signal-poor regions with diffuse borders.
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3.2. Ruptured plaque
Ruptured plaque is defined as an intimal interruption and cavity formation in the plaque. OCT
enables detection of ruptured plaque more frequently than IVUS. OCT examination after
thrombus aspiration in patients with ACS revealed that 73% of patients showed ruptured
plaque, and the mean thickness of the ruptured fibrous cap was 49 µm [15]. Ruptured plaque
was often observed in non-culprit lesions of ACS especially in diabetic patients, which showed
development of pan-coronary atherosclerosis.
3.3. Intracoronary thrombus
Intracoronary thrombus is a major cause of ACS, which is identified as an irregular high- or
low-backscattering mass protruding into the lumen. OCT can distinguish between thrombus
white and red thrombus [16]. White thrombus presents with a low-backscattering structure.
Red thrombus presents with a high-backscattering structure with signal-free shadowing.
3.4. Vasa vasorum
Vasa vasorum plays a pivotal role in coronary plaque growth by increasing red blood cells,
thereby supplying inflammatory cells and cytokines into the plaque. Sluimer et al. revealed
that vasa vasorum was increased in advanced plaques compared with early plaques in a
human  histological  study  [17].  OCT  has  been  proposed  as  a  high-resolution  imaging
modality that can identify vasa vasorum as microchannels with tiny black holes (50-100
µm). The proliferation of vasa vasorum has been identified recently as a common feature
of vulnerable plaque [18]. Kitabata et al. demonstrated increase of vasa vasorum counts in
TCFA [19]. An observational study of OCT revealed that the presence of vasa vasorum in
the plaques was also associated with positive remodeling and elevated high-sensitive C-
reactive protein levels. The OCT evaluation of vasa vasorum counts might be helpful for
assessing plaque vulnerability.
3.5. Spotty calcification
Clinical observations have suggested that the culprit lesions responsible for ACS are generally
less calcified than those responsible for stable angina pectoris (SAP), indicating that calcium
renders plaques more, rather than less stable [20]. However, the pattern of plaque calcification
may also matter; a small amount of calcium was reported as a characteristic of vulnerable
plaque that contributes to plaque instability. A pathological study by Burke et al. demonstrated
that plaque rupture and TCFA, considered to represent vulnerable plaque, were most
frequently associated with spotty calcification [21]. Previous IVUS studies have revealed a
positive relationship in patients with acute myocardial infarction (AMI) between small and
discrete calcifications within an arc of less than 90°, the presence of a fibrofatty plaque, and
positive remodeling of the culprit arterial segment [22]. Recently, two OCT clinical studies as
for spotty calcification (with an arc of <90°) have been reported. Kataoka Y et al. showed that
plaques containing spotty calcification exhibited a greater lipid plaque volume, thinner fibrous
caps (89.0 ± 31.6 µm vs. 136.5 ± 32.5 µm, P = 0.002) and a higher prevalence of vasa vasorum
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(45.9% vs. 17.7%, P = 0.007) in the culprit lesion of SAP patients [23]. Another study reported
by Mizukoshi M et al. showed that in the ACS patients compared with SAP patients spotty
calcification was more frequently observed in the ACS patients compared with SAP patients
and located close to the luminal surface [24]. Thus, spotty calcification detected by OCT was
positive relationship with plaque vulnerability.
3.6. Macrophage infiltration
Degradation of the fibrous cap matrix by macrophages is associated with atherosclerotic
plaque instability [25]. Macrophages infiltration detected by OCT were observed as a “bright
spot,” with a high signal variance from the surrounding tissue. Tearney et al. [26] and MacNeill
et al. [27] descried OCT was capable to evaluate cap macrophage content accurately. High
degree of positive correlation was observed between OCT and histological measurements of
macrophage density in fibrous cap (r < 0.84, P < 0.0001). OCT provided detection of cap
macrophage density >10% with 100% sensitivity and specificity [19].
3.7. Cholesterol crystal
Previous  studies  demonstrated  that  cholesterol  crystallization  is  higher  in  vulnerable
pathological  examination  [28].  Kellner-Weibel  et  al.  suggested  that,  within  the  lesion,
macrophages  may have  the  pivotal  role  in  initial  nucleation  and subsequent  growth of
cholesterol  crystals  [29].  Meanwhile,  it  has  been shown that  phagocytosis  of  cholesterol
crystals by macrophages causes and advances an inflammation in the atherosclerotic plaques
[30, 31]. OCT-imaging system with high-resolution could visualize structures suggestive of
accumulations of cholesterol crystals in vivo [6]. Cholesterol crystal by OCT was defined as
a thin linear region of  high density without attenuation [32].  Clinical  OCT studies have
suggested that cholesterol crystals frequently coexist with the major findings of vulnera‐
ble plaque (spotty calcification, vasa vasorum, and lipid-rich plaque), and are often seen in
poorly controlled diabetic patients [32].
4. In-stent neoatherosclerosis
In-stent neoatherosclerosis has been reported several years after drug-eluting stent (DES) and
bare-metal stent (BMS) implantation. Neoatherosclerosis is more frequent and occurs earlier
in patients undergoing DES implantation than those treated with BMS [33]. Neoatherosclerosis
includes lipid accumulation, calcium deposition, macrophage infiltration, neovascularization
within neointima, and results in very late stent failure including late stent thrombosis and in-
stent restenosis [34]. OCT studies have reported that in both BMS and DES, neointima in the
stent often comprises lipid-laden tissue in late phase of stent implantation and that expansion
of neovascularization from peri-stent to intra-intima leads to atherosclerotic progression of
neointima [35, 36]. Although the causes of neoatherosclerosis are unknown, Kato et al. recently
showed that predictors of neoatherosclerosis are old stent age ≥48 months, DES usage, age ≥65
years old, current smoking, and chronic kidney disease [37].
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5. Relationship vulnerable plaque by OCT and no-reflow phenomenon
Primary PCI is widely performed for patients with coronary artery disease. Sometimes, no-
reflow phenomenon occurred during PCI in both patients with ACS and SAP, and no-reflow
after PCI is associated with poor functional and clinical patient outcomes when compared with
patients with adequate reflow [38, 39]. Thus, accurately detecting high-risk lesions of no-reflow
phenomenon is warranted for interventional cardiologists. Recent OCT studies have shown
that some vulnerable findings (lipid-rich plaque, TCFA, and spotty calcification) are predictors
of no-reflow phenomenon. Ikenaga et al. showed that length of lipid pool was longer in the
ST-segment resoluton (−) group than in the ST-segment resoluton (+) group in patients with
ST elevation myocardial infarction (10.1 ± 2.8 mm and 7.8 ± 3.2 mm, p = 0.02) [40]. Lee et al.
showed that TCFA was associated with cardiac troponin I elevation after PCI and the presence
of TCFA was an independent predictor of periprocedural myocardial infarction (odds ratio,
10.47; 95% confidence interval, 3.74–29.28; P < 0.001) [39]. Tanaka et al. showed that TCFA was
more often observed in the no-reflow group than in the reflow group (50% vs. 16%, P = 0.005)
and the frequency of the no-reflow phenomenon increased according to the size of the lipid
arc in the culprit lesion in patients with ACS (Lipid arc 1–90°, 4.7%; 91–180°, 35%; 181–360°,
75%) [41]. Furthermore, Ueda et al. showed that colocalization of TCFA and spotty calcification
was an independent predictor of PCI-related cardiac troponin T elevation (odds ratio 8.40, 95%
confidence interval 1.65–52.78, P < 0.01) [42]. Thus, OCT could be a useful tool for risk
stratification of PCI.
6. Considering optimal medical therapy for vulnerable plaque with OCT
Atherosclerosis has an important inflammatory component and acute cardiovascular events
can be initiated by inflammatory processes occurring in vulnerable plaques. The current
understanding of the major cause of ACS is that it results from rupture of a vulnerable plaque.
OCT is a high-resolution imaging technology that can provide detailed observation of the
vulnerable coronary plaque. TCFA is the most typical OCT findings as a vulnerable plaque.
OMT is regarded as one of the effective treatments for the stabilization of coronary vulnerable
plaques, and it reduces the risk of coronary events and mortality. Intensive lipid-lowering
therapy with statins is regarded as one of the effective treatments for the stabilization of
coronary artery plaques, and reduces the risk for coronary events and mortality [43]. Serial
OCT observations could explain this efficacy of statin therapy. Takarada et al. showed that
statin therapy for 9 months after the onset of AMI significantly increased the fibrous-cap
thickness in patients with hyperlipidemia (151 +/- 110 µm to 280 +/- 120 µm, P < 0.01) [44].
However, cardiovascular events occur in some patients even with statin therapy, and residual
risk has become a problem. Habara et al. showed the effect of ezetimibe in addition to
fluvastatin on the progression of coronary vulnerable plaque evaluated by OCT. The change
in the fibrous cap thickness was significantly greater in the ezetimibe and fluvastatin group
than in the fluvastatin alone group (0.08 ± 0.08 mm vs 0.04 ± 0.06 mm, P < 0.001) [45]. The Japan
EPA (eicosapentaenoic acid) Lipid Intervention Study, which was a large randomized clinical
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trial, showed that purified EPA administration along with statin therapy reduced the incidence
of coronary events by 19% [46]. Hasegawa et al. showed that lower EPA/AA ratio was
associated with higher vulnerability of coronary plaques by OCT examination. The low EPA/
AA group had wider maximum lipid arc (114.0 ± 94.8° vs. 56.4 ± 66.0°, p = 0.0097), longer lipid
length (4.8 ± 4.5 mm vs. 1.6 ± 2.6 mm, p = 0.0037), and thinner fibrous cap (69.3 ± 28.3 µm vs.
113.3 ± 46.6 µm, p = 0.005) compared with the high EPA/AA group [47]. Nishio et al. showed
that the EPA and statin group had a greater increase in fibrous-cap thickness, with a greater
decrease in lipid arc and lipid length compared with the statin alone group [48].
7. Conclusion
OCT is a high-resolution imaging technology that can provide detailed observation of
vulnerable coronary atherosclerotic plaques in clinical settings. Since only OCT imaging of
coronary artery is not able to accurately predict the future adverse events in patients with
coronary artery disease (CAD), bringing together clinical data obtained by OCT with clinical
data will improve future outcome of patients with CAD. Further developments in imaging
technology could enable cardiologists to precisely detect vulnerable plaques in coronary artery
and to improve more optimal treatments for vulnerable patients.
Author details
Takao Hasegawa and Kenei Shimada*
*Address all correspondence to: shimadak@med.osaka-cu.ac.jp
Department of Internal Medicine and Cardiology, Osaka City University Graduate School of
Medicine, Abeno-ku, Osaka, Japan
References
[1] Bourantas CV, Garcia-Garcia HM, Serruys PW. Letter by Bourantas et al. regarding
article, "Nonculprit plaques in patients with acute coronary syndromes have more
vulnerable features compared with those with non-acute coronary syndromes: a 3-
vessel optical coherence tomography study." Circ Cardiovasc Imaging. 2012 Nov;
5(6):e68. 23169984.
[2] Kato K, Yonetsu T, Kim SJ, Xing L, Lee H, McNulty I, et al. Nonculprit plaques in
patients with acute coronary syndromes have more vulnerable features compared
with those with non-acute coronary syndromes: a 3-vessel optical coherence tomog‐
raphy study. Circ Cardiovasc Imaging. 2012 Jul;5(4):433-40. 22679059.
Coronary Artery Disease - Assessment, Surgery, Prevention106
[3] Ambrose JA. In search of the "vulnerable plaque." Can it be localized and will focal
regional therapy ever be an option for cardiac prevention? J Am Coll Cardiol. 2008
Apr 22;51(16):1539-42. 18420095.
[4] Kume T, Akasaka T, Kawamoto T, Watanabe N, Toyota E, Neishi Y, et al. Assess‐
ment of coronary arterial plaque by optical coherence tomography. Am J Cardiol. 2006
Apr 15;97(8):1172-5. 16616021.
[5] Rieber J, Meissner O, Babaryka G, Reim S, Oswald M, Koenig A, et al. Diagnostic ac‐
curacy of optical coherence tomography and intravascular ultrasound for the detec‐
tion and characterization of atherosclerotic plaque composition in ex-vivo coronary
specimens: a comparison with histology. Coron Artery Dis. 2006 Aug;17(5):425-30.
16845250.
[6] Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, et al. Consen‐
sus standards for acquisition, measurement, and reporting of intravascular optical
coherence tomography studies: a report from the International Working Group for
Intravascular Optical Coherence Tomography Standardization and Validation. J Am
Coll Cardiol. 2012 Mar 20;59(12):1058-72. 22421299.
[7] Takano M, Jang IK, Inami S, Yamamoto M, Murakami D, Okamatsu K, et al. In vivo
comparison of optical coherence tomography and angioscopy for the evaluation of
coronary plaque characteristics. Am J Cardiol. 2008 Feb 15;101(4):471-6. 18312760.
[8] Kubo T, Matsuo Y, Ino Y, Tanimoto T, Ishibashi K, Komukai K, et al. Optical coher‐
ence tomography analysis of attenuated plaques detected by intravascular ultra‐
sound in patients with acute coronary syndromes. Cardiol Res Pract.
2011;2011:687515. 21941667. Pubmed Central PMCID: 3173965.
[9] Sukiennik A, Radomski M, Rychter M, Kubica J. Usefulness of optical coherence to‐
mography in the assessment of atherosclerotic culprit lesions in acute coronary syn‐
dromes. Comparison with intravascular ultrasound and virtual histology. Cardiol J.
2008;15(6):561-3. 19039763.
[10] Takarada S, Imanishi T, Ishibashi K, Tanimoto T, Komukai K, Ino Y, et al. The effect
of lipid and inflammatory profiles on the morphological changes of lipid-rich pla‐
ques in patients with non-ST-segment elevated acute coronary syndrome: follow-up
study by optical coherence tomography and intravascular ultrasound. JACC Cardio‐
vasc Intervent. 2010 Jul;3(7):766-72. 20650439.
[11] Matsuo Y, Kubo T, Okumoto Y, Ishibashi K, Komukai K, Tanimoto T, et al. Circulat‐
ing malondialdehyde-modified low-density lipoprotein levels are associated with the
presence of thin-cap fibroatheromas determined by optical coherence tomography in
coronary artery disease. Eur Heart J Cardiovasc Imaging. 2013 Jan;14(1):43-50.
22573905.
[12] Iguchi T, Hasegawa T, Otsuka K, Matsumoto K, Yamazaki T, Nishimura S, et al. In‐
sulin resistance is associated with coronary plaque vulnerability: insight from optical
Optical Coherence Tomography for the Assessment of Coronary Plaque Vulnerability
http://dx.doi.org/10.5772/61615
107
coherence tomography analysis. Eur Heart J Cardiovasc Imaging. 2014 Mar;15(3):
284-91. 24022065.
[13] Bouki KP, Katsafados MG, Chatzopoulos DN, Psychari SN, Toutouzas KP, Chara‐
lampopoulos AF, et al. Inflammatory markers and plaque morphology: an optical co‐
herence tomography study. Int J Cardiol. 2012 Feb 9;154(3):287-92. 20974497.
[14] Uemura S, Ishigami K, Soeda T, Okayama S, Sung JH, Nakagawa H, et al. Thin-cap
fibroatheroma and microchannel findings in optical coherence tomography correlate
with subsequent progression of coronary atheromatous plaques. Eur Heart J. 2012
Jan;33(1):78-85. 21831910.
[15] Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, et al. Assessment of
culprit lesion morphology in acute myocardial infarction: ability of optical coherence
tomography compared with intravascular ultrasound and coronary angioscopy. J Am
Coll Cardiol. 2007 Sep 4;50(10):933-9. 17765119.
[16] Kume T, Akasaka T, Kawamoto T, Ogasawara Y, Watanabe N, Toyota E, et al. As‐
sessment of coronary arterial thrombus by optical coherence tomography. Am J Car‐
diol. 2006 Jun 15;97(12):1713-7. 16765119.
[17] Sluimer JC, Kolodgie FD, Bijnens AP, Maxfield K, Pacheco E, Kutys B, et al. Thin-
walled microvessels in human coronary atherosclerotic plaques show incomplete en‐
dothelial junctions relevance of compromised structural integrity for intraplaque
microvascular leakage. J Am Coll Cardiol. 2009 Apr 28;53(17):1517-27. 19389562.
Pubmed Central PMCID: 2756458.
[18] Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intrapla‐
que hemorrhage and progression of coronary atheroma. New Eng J Med. 2003 Dec
11;349(24):2316-25. 14668457. Epub 2003/12/12. eng.
[19] Kitabata H, Tanaka A, Kubo T, Takarada S, Kashiwagi M, Tsujioka H, et al. Relation
of microchannel structure identified by optical coherence tomography to plaque vul‐
nerability in patients with coronary artery disease. Am J Cardiol. 2010 Jun 15;105(12):
1673-8. 20538113.
[20] Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S. Relationship of clinical presenta‐
tion and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol.
2001 Oct;21(10):1618-22. 11597935. Epub 2001/10/13. eng.
[21] Burke AP, Weber DK, Kolodgie FD, Farb A, Taylor AJ, Virmani R. Pathophysiology
of calcium deposition in coronary arteries. Herz. 2001 Jun;26(4):239-44. 11479935.
Epub 2001/08/02. eng.
[22] Fujii K, Carlier SG, Mintz GS, Takebayashi H, Yasuda T, Costa RA, et al. Intravascu‐
lar ultrasound study of patterns of calcium in ruptured coronary plaques. Am J Cardi‐
ol. 2005 Aug 1;96(3):352-7. 16054456. Epub 2005/08/02. eng.
[23] Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, et al. Spotty calcifi‐
cation and plaque vulnerability in vivo: frequency-domain optical coherence tomog‐
Coronary Artery Disease - Assessment, Surgery, Prevention108
raphy analysis. Cardiovasc Diagn Ther. 2014 Dec;4(6):460-9. 25610803. Pubmed Central
PMCID: 4278040.
[24] Mizukoshi M, Kubo T, Takarada S, Kitabata H, Ino Y, Tanimoto T, et al. Coronary
superficial and spotty calcium deposits in culprit coronary lesions of acute coronary
syndrome as determined by optical coherence tomography. Am J Cardiol. 2013 Jul
1;112(1):34-40. 23540654.
[25] Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltra‐
tion in acute coronary syndromes. Implications for plaque rupture. Circulation. 1994
Aug;90(2):775-8. 8044947. Epub 1994/08/01. eng.
[26] Tearney GJ, Yabushita H, Houser SL, Aretz HT, Jang IK, Schlendorf KH, et al. Quan‐
tification of macrophage content in atherosclerotic plaques by optical coherence to‐
mography. Circulation. 2003 Jan 7;107(1):113-9. 12515752. Epub 2003/01/08. eng.
[27] Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF, et al. Pat‐
terns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study.
Circulation. 1996 Sep 15;94(6):1247-54. 8822976. Epub 1996/09/15. eng.
[28] Abela GS, Aziz K, Vedre A, Pathak DR, Talbott JD, Dejong J. Effect of cholesterol
crystals on plaques and intima in arteries of patients with acute coronary and cere‐
brovascular syndromes. Am J Cardiol. 2009 Apr 1;103(7):959-68. 19327423. Epub
2009/03/31. eng.
[29] Kellner-Weibel G, Yancey PG, Jerome WG, Walser T, Mason RP, Phillips MC, et al.
Crystallization of free cholesterol in model macrophage foam cells. Arterioscler
Thromb Vasc Biol. 1999 Aug;19(8):1891-8. 10446067. Epub 1999/08/14. eng.
[30] Rajamaki K, Lappalainen J, Oorni K, Valimaki E, Matikainen S, Kovanen PT, et al.
Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a
novel link between cholesterol metabolism and inflammation. PloS One.
2010;5(7):e11765. 20668705. Pubmed Central PMCID: PMC2909263. Epub 2010/07/30.
eng.
[31] Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3
inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Nature. 2010 Apr 29;464(7293):1357-61. 20428172. Pubmed Central PMCID:
PMC2946640. Epub 2010/04/30. eng.
[32] Nakamura S, Inami S, Murai K, Takano M, Takano H, Asai K, et al. Relationship be‐
tween cholesterol crystals and culprit lesion characteristics in patients with stable
coronary artery disease: an optical coherence tomography study. Clin Res Cardiol: Of‐
ficial Journal of the German Cardiac Society. 2014 Dec;103(12):1015-21. 25086962.
[33] Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The
pathology of neoatherosclerosis in human coronary implants bare-metal and drug-
Optical Coherence Tomography for the Assessment of Coronary Plaque Vulnerability
http://dx.doi.org/10.5772/61615
109
eluting stents. J Am Coll Cardiol. 2011 Mar 15;57(11):1314-22. 21376502. Pubmed Cen‐
tral PMCID: 3093310.
[34] Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final
common pathway of late stent failure. J Am Coll Cardiol. 2012 Jun 5;59(23):2051-7.
22651862.
[35] Takano M, Yamamoto M, Inami S, Murakami D, Ohba T, Seino Y, et al. Appearance
of lipid-laden intima and neovascularization after implantation of bare-metal stents
extended late-phase observation by intracoronary optical coherence tomography. J
Am Coll Cardiol. 2009 Dec 29;55(1):26-32. 20117359.
[36] Kang SJ, Mintz GS, Akasaka T, Park DW, Lee JY, Kim WJ, et al. Optical coherence
tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implanta‐
tion. Circulation. 2011 Jun 28;123(25):2954-63. 21646494.
[37] Yonetsu T, Kato K, Kim SJ, Xing L, Jia H, McNulty I, et al. Predictors for neoathero‐
sclerosis: a retrospective observational study from the optical coherence tomography
registry. Circ Cardiovasc Imaging. 2012 Sep 1;5(5):660-6. 22798521.
[38] Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al. Angiograph‐
ic no-reflow phenomenon as a predictor of adverse long-term outcome in patients
treated with percutaneous transluminal coronary angioplasty for first acute myocar‐
dial infarction. J Am Coll Cardiol. 2000 Oct;36(4):1202-9. 11028471.
[39] Lee T, Yonetsu T, Koura K, Hishikari K, Murai T, Iwai T, et al. Impact of coronary
plaque morphology assessed by optical coherence tomography on cardiac troponin
elevation in patients with elective stent implantation. Circ Cardiovasc Intervent. 2011
Aug;4(4):378-86. 21791670.
[40] Ikenaga H, Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Miura F, et al. Longitudinal
extent of lipid pool assessed by optical coherence tomography predicts microvascu‐
lar no-reflow after primary percutaneous coronary intervention for ST-segment ele‐
vation myocardial infarction. J Cardiol. 2013 Aug;62(2):71-6. 23680004.
[41] Tanaka A, Imanishi T, Kitabata H, Kubo T, Takarada S, Tanimoto T, et al. Lipid-rich
plaque and myocardial perfusion after successful stenting in patients with non-ST-
segment elevation acute coronary syndrome: an optical coherence tomography
study. Eur Heart J. 2009 Jun;30(11):1348-55. 19383736.
[42] Ueda T, Uemura S, Watanabe M, Sugawara Y, Soeda T, Okayama S, et al. Colocaliza‐
tion of thin-cap fibroatheroma and spotty calcification is a powerful predictor of pro‐
cedure-related myocardial injury after elective coronary stent implantation. Coron
Artery Dis. 2014 Aug;25(5):384-91. 24681754.
[43] LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive
lipid lowering with atorvastatin in patients with stable coronary disease. New Eng J
Med. 2005 Apr 7;352(14):1425-35. 15755765.
Coronary Artery Disease - Assessment, Surgery, Prevention110
[44] Takarada S, Imanishi T, Kubo T, Tanimoto T, Kitabata H, Nakamura N, et al. Effect
of statin therapy on coronary fibrous-cap thickness in patients with acute coronary
syndrome: assessment by optical coherence tomography study. Atherosclerosis. 2009
Feb;202(2):491-7. 18572175.
[45] Habara M, Nasu K, Terashima M, Ko E, Yokota D, Ito T, et al. Impact on optical co‐
herence tomographic coronary findings of fluvastatin alone versus fluvastatin + eze‐
timibe. Am J Cardiol. 2014 Feb 15;113(4):580-7. 24388622.
[46] Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Ef‐
fects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic pa‐
tients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007 Mar
31;369(9567):1090-8. 17398308.
[47] Hasegawa T, Otsuka K, Iguchi T, Matsumoto K, Ehara S, Nakata S, et al. Serum n-3
to n-6 polyunsaturated fatty acids ratio correlates with coronary plaque vulnerabili‐
ty: an optical coherence tomography study. Heart Vess. 2014 Sep;29(5):596-602.
24005765.
[48] Nishio R, Shinke T, Otake H, Nakagawa M, Nagoshi R, Inoue T, et al. Stabilizing ef‐
fect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fi‐
broatheroma. Atherosclerosis. 2014 May;234(1):114-9. 24637411.
Optical Coherence Tomography for the Assessment of Coronary Plaque Vulnerability
http://dx.doi.org/10.5772/61615
111

